Investigating the Interactive Effects of Berberine and Sitagliptin on Lipid Profile, Glucose and Insulin Levels in Diabetic Male Rats with Fatty Liver

Subject Areas : Journal of Animal Biology

Soraya Mehrdoost ¹ , Parichehreh Yaghmaei ² , Hanieh Jafary ³ , Azadeh Ebrahim-Habibi ⁴

1 - Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
4 - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Received: 2023-04-29 Accepted : 2023-06-10 Published : 2024-02-20

Keywords: Insulin resistance, Fatty liver, Berberine, Type 2 diabetes, Sitagliptin,

Abstract :

Hepatic insulin resistance is associated with NAFLD and it is a major factor in the pathogenesis of type 2 diabetes and metabolic syndrome. Insulin resistance causes lipolysis in adipose tissue and disturbance in the regulation of lipid metabolism causes fat accumulation in the liver. In this study, the biological activities of Berberine and Sitagliptin to improve insulin resistance and lipid profile in Sprague-Dawley rats with type 2 diabetes was investigated. groups include 1: control (physiological serum as an alloxan solvent); 2: model (fatty liver + Alloxan); 3: Sitagliptin (fatty liver + Alloxan and Sitagliptin 10 mg/kg); 4: Berberine (fatty liver + Alloxan and Berberine 150mg/kg); 5: Berberine/Sitagliptin (fatty liver + Alloxan and Sitagliptin 5 mg/kg and Berberine 75 mg/kg). At the end of the treatment period, under anesthesia, Blood sampling done from the heart and lipid profile, glucose and insulin measured. The amount of triglyceride (p < 0.01), cholesterol (p < 0.05), LDL (p < 0.01), FFA (p < 0.05), fasting glucose (p < 0.05) and insulin (p < 0.01) in the coadministration group decreased compared to the model group and HDL increased, which was not significant. Berberine and Sitagliptin, especially when administered together, have a favorable effect on lipid metabolism and insulin resistance and can be considered as an effective treatment regimen for hyperlipidemia and fatty liver.  

References:

1. Abidi P., Zhou Y., Jiang J.D., Liu J. 2005. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(10):2170-2176.


2. Abud M.A., Nardello A.L., Torti J.F. 2017. Hypoglycemic effect due to insulin stimulation with Plantago major in wistar rats. Medicinal and Aromatic Plants, 6(3).


3. Akaslan S.B., Degertekin C.K., Yilmaz G., Cakir N., Arslan M., Toruner F.B. 2013. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metabolic Syndrome and Related Disorders, 11(4):243-250.


4. Alam S., Mustafa G., Alam M., Ahmad N. 2016. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World Journal of Gastrointestinal Pathophysiology, 7(2):211-217.


5. Bai M., Y. Liu, F. Zhou, Y. Zhang, Q. Zhu, L. Zhang, Q. Zhang, S. Wang, K. Zhu, X. Wang and L. Zhou 2018. Berberine inhibits glucose oxidation and insulin secretion in rat islets. Endocrinology Journal, 65(4):469-477.


6. Cameron J., Ranheim T., Kulseth M.A., Leren T.P., Berge K.E. 2008. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis, 201(2):266-273.


7. Chen L., Teng H., Cao H. 2019. Chlorogenic acid and caffeic acid from Sonchus oleraceus Linn synergistically attenuate insulin resistance and modulate glucose uptake in HepG2 cells. Food Chemistry and Toxicology, 127:182-187.


8. Fan M., Li Y., Zhang S. 2016. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: A meta-analysis of randomized clinical trials. Medicine, 95(2):e2386-e2386.


9. Gomez-Peralta F., Abreu C., Gomez-Rodriguez S., Barranco R.J., Umpierrez G.E. 2018. Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. Diabetes Therapy, 9(5):1775-1789.


10. Goossens G.H. 2008. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav , 94(2): 206-218.


11. Hsieh J., Longuet C., Baker C.L., Qin B., Federico L.M., Drucker D.J., K. Adeli 2010. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 53(3):552-561.


12. Hussain M., Atif M.A., Ghafoor M.B. 2016. Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients. Pakistan Journal of Pharmaceutical Sciences, 29(6):2385-2389.


13. Ju J., J. Li, Q. Lin and H. Xu 2018. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine, 50:25-34.


14. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 10(12):1344-1351.


15. Kong W.J., Zhang H., Song D.Q., Xue R., Zhao W., Wei J., Wang Y.M., Shan N., Zhou Z.X., Yang P., You X.F., Li Z.R., Si S.Y., Zhao L.X., Pan H.N., Jiang J.D. 2009. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, 58(1):109-119.


16. Kutoh E., Wada A., Hayashi J. 2018. Regulation of free fatty acid by sitagliptin monotherapy in drug-naive subjects with type 2 diabetes. Endocrine Practice, 24(12):1063-1072.


17. Lewis G.F., A. Carpentier, K. Adeli and A. Giacca 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews, 23(2):201-229.


18. Li S., Chen H., Wang J., Wang X., Hu B., Lv F. 2015. Involvement of the PI3K/Akt signal pathway in the hypoglycemic effects of tea polysaccharides on diabetic mice. International Journal of Biological Macromolecules, 81:967-974.


19. Lin C.H., Lin C.C. 2016. Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition. Experimental and Therapeutic Medicine, 11(6):2609-2615.


20. Liu D., Zhang Y., Liu Y., Hou L., Li S., Tian H., Zhao T. 2018. Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Experimental and Clinical Endocrinology and Diabetes, 126(8):513-520.


21. Maiztegui B., Borelli M.I., Madrid V.G., Del Zotto H., Raschia M.A., Francini F., Massa M.L., Flores L.E., Rebolledo O.R., Gagliardino J.J. 2011. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clinical Sciences, 120(2):73-80.


22. McCullough A.J. 2006. Pathophysiology of nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology, 40(1):S17-29.


23. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., Zhang B.B. 2006. Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes. Diabetes, 55(6):1695-1704.


24. Rhodes C.J. 2005. Type 2 diabetes-a matter of beta-cell life and death? Science, 307(5708): 380-384.


25. Sanyal A.J. 2005. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol, 2(1):46-53.


26. Shen T., Xu B., Lei T., Chen L., Zhang C., Ni Z. 2018. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and Therapeutic Medicine, 16(4):3121-3128.


27. Shirakawa J., Fujii H., Ohnuma K., Sato K., Ito Y., Kaji M., Sakamoto E., Koganei M., Sasaki H., Nagashima Y., Amo K., Aoki K., Morimoto C., Takeda E., Terauchi Y. 2011. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes, 60(4):1246-1257.


28. Taniguchi C.M., Emanuelli B., Kahn C.R. 2006. Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology, 7(2):85-96.


29. Van Bloemendaal L., Ten Kulve J.S., la Fleur S.E., Ijzerman R.G., Diamant M. 2014. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology, 221(1):T1-16.


30. Vuddanda P.R., Chakraborty S., Singh S. 2010. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opinion on Investigational Drugs, 19(10):1297-1307.


31. Wang Y., Yan A., Li S., Liu B., Li H., Yan Y. 2019. Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. Medicine, 98(35): e16947-e16947.


32. Wu Q.M., Ni H.X., Lu X. 2016. Changes of adipocytokine expression after diabetic rats received sitagliptin and the molecular mechanism. Asian Pacific Journal of Tropical Medicine, 9(9):893-897.


33. Xu B., Shen T., Chen L., Xia J., Zhang C., Wang H., Yu M., Lei T. 2017. The effect of sitagliptin on lipid metabolism of fatty liver mice and related mechanisms. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 23:1363-1370.


34. Xu G., Huang K., Zhou J. 2018. Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products. Current Medicinal Chemistry, 25(8):889-907.


35. Zhang H., Wei J., Xue R., Wu J.D., Zhao W., Wang Z.Z., Wang S.K., Zhou Z.X., Song D.Q., Wang Y.M., Pan H.N., Kong W.J., Jiang J.D. 2010. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59(2):285-292.


36. Zhang N., Liu X., Zhuang L., Liu X., Zhao H., Shan Y., Liu Z., Li F., Wang Y., Fang J. 2020. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regulatory Toxicology and Pharmacology, 110:104544.


37. Zhu X., Yang J., Zhu W., Yin X., Yang B., Wei Y., Guo X. 2018. Combination of berberine with resveratrol improves the lipid-lowering efficacy. International Journal of Molecular Sciences, 19(12).


38. Zou Y., Li J., Lu C., Wang J., Ge J., Huang Y., Zhang L., Wang Y. 2006. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Science, 79(11):1100-1107.